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Retinopathy is a common complication of diabetes, and
is the principal cause of blindness in the adult population.
Biochemical  abnormalities  postulated  to  contribute  to  the
development of this retinopathy have been numerous [1-5],
including  signaling  via  advanced  glycation  endproducts
(AGEs) and the receptor for advanced glycation end products
(RAGE). Increased formation of AGEs is one of the best-
recognized biochemical abnormalities of diabetes. RAGE is
a  multiligand  receptor  that  mediates  many  or  all  of  the
sequelae of AGEs interacting with the cell surface, but it also
binds other ligands, including S100/calgranulins, amphoterin/
High mobility group box 1 (HMGB1), and amyloid fibrils.
AGEs interact with RAGE to induce proinflammatory, pro-
adhesive, and growth-stimulating signals, and these changes
have been associated with or causally linked to abnormalities
in several cell types and tissues [2,6-8].
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The AGE:RAGE axis is also active in the retina [2,9,
10]. Soluble RAGE (sRAGE), a secreted isoform that acts as
a competitive inhibitor of AGE-mediated alterations in cells,
has been shown to inhibit diabetes-induced changes in retinal
histology  and  in  electroretinograms  produced  with  an
experimental  model  of  diabetic  retinopathy  [9].  Since  a
growing body of work implicates inflammation and nitric
oxide  in  the  development  of  the  early  stages  of  diabetic
retinopathy [4,5,11-15], we evaluated the effects of a new
fusion protein inhibitor of RAGE signaling (RAGE-Ig fusion
protein) on the development of diabetes-induced alterations
in  retinal  physiology,  inflammation  and  histopathology  in
C57Bl/6J mice. To determine whether or not the effects of the
drug were limited to retinas in diabetes cases, we also assessed
the effects of the drug on a parameter of diabetes-induced
sensory  neuropathy  (sensitivity  to  light  touch,  i.e.,  tactile
allodynia) in peripheral nerves.
METHODS
Experimental animals: Male C57Bl/6J mice were randomly
assigned  to  become  diabetic  or  remain  untreated  in  the
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Purpose: The receptor for advanced glycation end products (RAGE) has been implicated in the pathogenesis of numerous
complications of diabetes. We assessed the effect of a novel RAGE fusion protein inhibitor on retinal histopathology and
nerve function, and on retinal inflammation and oxidative stress.
Methods: C57BL/6J mice were made diabetic with streptozotocin, and some were given a RAGE fusion protein (10, 100,
or 300 µg per mouse 3 times per week). Mice were sacrificed at 2 months and 10 months into the study to assess retinal
vascular histopathology, accumulation of albumin in the neural retina, cell loss in the ganglion cell layer, and biochemical
and physiologic abnormalities in the retina. Tactile allodynia (light touch) was measured on a paw of each animal at 2
months.
Results: Leukostasis, expression of the intercellular adhesion molecule-1 (ICAM-1), accumulation of albumin in the
neural retina, and nitration of retinal proteins were significantly increased in the retinas of mice diabetic for 2 months.
The number of degenerate retinal capillaries was significantly increased in mice diabetic for 10 months, compared to the
nondiabetic controls. Diabetes also enhanced sensitivity of peripheral nerves to tactile allodynia. All three doses of the
RAGE fusion protein inhibited capillary degeneration, accumulation of albumin in the neural retina, nitration of retinal
proteins, and tactile allodynia, demonstrating that biologically meaningful levels of the drug reached the retina. RAGE
inhibition did tend to inhibit diabetes-induced retinal leukostasis and ICAM-1 expression (previously postulated to be
important in the pathogenesis of retinopathy), but these effects were not statistically significant for the use of the lower
doses of the drug that normalized the vascular histopathology.
Conclusions: Inhibition of RAGE blocked the development of important lesions of diabetic retinopathy, but these
beneficial effects seemed not to be mediated via leukostasis. RAGE inhibition also blocked the development of sensory
allodynia in diabetes. RAGE is an important therapeutic target to inhibit the development of vascular and neural
complications of diabetes.nondiabetic group. Diabetes was induced by five sequential
daily intraperitoneal injections of a freshly prepared solution
of streptozotocin in citrate buffer (pH 4.5) at 60 mg/kg of
bodyweight. After hyperglycemia was verified at least three
times during the second week after streptozotocin, diabetic
mice randomly were assigned to be untreated diabetic controls
or  to  be  administered  the  RAGE-Ig  fusion  protein
intraperitoneally at three different concentrations (10, 100,
and 300 µg per mouse) three times per week. We observed no
adverse effects of any dose of the RAGE-Ig fusion protein on
the bodyweight gain or overall health of the diabetic mice.
Insulin  was  given  as  needed  to  prevent  weight  loss,  but
without  preventing  hyperglycemia  or  glucosuria  (0.0–0.2
units of Neutral Protamine Hagedorn insulin subcutaneously,
zero  to  three  times  per  week).  Glycohemoglobin  was
measured  using  the  Bio-Rad  Total  Glycated  Hemoglobin
Assay (Bio-Rad, Hercules, CA) every 2–3 months and just
before  the  animals  were  killed.  Food  consumption  and
bodyweight were measured weekly. The animals were studied
either for a 10-month duration of diabetes to investigate the
effects of the therapy on the retinal histopathology, or for a 2-
month  duration  to  investigate  the  therapy’s  effects  on
molecular  and  physiologic  changes.  The  treatment  of  all
animals used in this study conformed to the ARVO Resolution
on the Treatment of Animals in Research.
The  RAGE  fusion  protein  (provided  by  L.  Brown,
Galactica     Pharmaceuticals,    Villanova,    PA)     consists 
of   a   RAGE    ligand-binding     element,    a      heavy-chain
immunoglobulin of a G4 isotype constant domain, and a linker
connecting  the  ligand-binding  element  with  the  constant
domain. The RAGE-Fc (Fragment, crystallizable region of the
antibody) binds to all of the known ligands of RAGE, and acts
as a competitive, negative regulator of RAGE signaling by
competing  with  membrane-bound  receptors  for  binding
ligands. As demonstrated previously [16], the binding of the
soluble RAGE to its ligands inhibits the binding of those
ligands to membrane-based RAGEs. The available evidence
indicates a strong affinity of this RAGE fusion protein for
HMGB1 (not shown), and we speculate that most of the effects
seen with this inhibitor are mediated through the binding of
HMGB1. For the present study, a murine version of human
RAGE was employed in which a G2a isotype constant domain
(biologically equivalent to the G4 isotype in the hRAGE) was
used. The molecule was created in Chinese hamster ovary
cells cells using the GPEx expression system (Gala Biotech,
Middleton, WI). The molecule has a molecular weight of
approximately 140 kDa.
Diabetes-induced retinal histopathology: After 10 months of
diabetes, the mouse eyes were fixed in formalin, and one retina
from  each  animal  was  isolated,  washed  in  running  water
overnight, and digested for 2 h in Difco crude trypsin solution
(Cat no. 15090–046; Invitrogen Corp., Carlsbad, CA), as we
have reported previously [17-20]. When totally cleaned of
neural cells, the isolated vasculature was laid out on a glass
microscope slide, dried overnight, stained with hematoxylin
and  periodic  acid  (Schiff  base;  Sigma-Aldrich,  St.  Louis,
MO), dehydrated, and coverslipped. Degenerate (acellular)
capillaries  were  quantitated  in  six  to  seven  field  areas
corresponding  to  the  midretina  (200×  magnification)  in  a
masked  manner.  Acellular  capillaries  were  identified  as
capillary-sized vessel tubes having no nuclei anywhere along
their length, and were reported per square millimeter of retinal
area. Pericyte “ghosts” were estimated from the prevalence of
protruding “bumps” in the capillary basement membranes
from which pericytes had disappeared. At least 1,000 capillary
cells (endothelial cells and pericytes) in five field areas in the
mid-retina  were  examined  (at  400×  magnification)  in  a
masked manner. Ghosts on any already acellular vessels were
excluded.
To  study  the  effects  of  diabetes  on  retinal
neurodegeneration, the cells in the ganglion cell layer were
counted. The formalin-fixed eyes were embedded in paraffin,
sectioned sagittally through the retina including through the
optic nerve, and stained with hematoxylin-eosin. The number
of cells in the ganglion cell layer was counted in two areas
(the midretina and the posterior retina adjacent to the optic
nerve) on both sides of the optic nerve. Comparable areas from
both sides of the optic nerve were averaged and expressed per
unit length.
Adhesion of white blood cells to retinal blood vessels: After
2 months of diabetes, blood was removed from the vasculature
of  anesthetized  animals  by  complete  perfusion  with
phosphate-buffered saline (0.01 M phosphate buffer, 0.0027
M potassium chloride and 0.137 M sodium chloride, pH 7.4;
Sigma-Aldrich, St. Louis, MO) via a heart catheter. Animals
were then perfused with fluorescein-coupled concanavalin A
lectin (20 μg/ml in PBS; Vector Laboratories, Burlingame,
CA), as described previously by us and others [19,21-23].
Flatmounted  retinas  were  imaged  via  fluorescence
microscopy, and the number of leukocytes adherent to the
vascular wall was counted.
Leakage of albumin into neural retina: The amount of leakage
of albumin into the neural retina was used to estimate vascular
permeability.  After  2  months  of  diabetes,  the  eyes  were
cryosectioned (section thickness: 10 µm), fixed in methanol
for  10  min,  and  washed  (4×  in  PBS).  Each  section  was
incubated  in  sheep  antimouse  serum  albumin  (AB8940;
1:2,000 dilution; Abcam, Cambridge, MA) for 2 h. After
washing,  sections  were  incubated  in  fluorescein
isothiocyanate-labeled secondary antibody for 90 min (AB
6743;  1:1,000  dilution;  Abcam).  Under  fluorescence
microscopy,  the  average  amount  of  fluorescence  was
determined in each of four retinal layers (the inner plexiform
layer, inner nuclear layer, outer plexiform layer, and outer
nuclear layer). Measurements were made in three replicate
areas in each retinal layer, both at midretina and beside the
optic nerve. The amount of fluorescence at each site was the
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(NIS  Elements  126  BR  3.00;  Nikon  Instruments,  Inc.,
Melville, NY).
Nitration  of  retinal  proteins:  After  2  months  of  diabetes,
retinas were isolated and homogenized. Dot blots were made,
blotting 50 µg protein homogenate from each animal onto
nitrocellulose membranes. The membranes were blocked with
milk  (5%),  washed,  and  immunostained  using
antinitrotyrosine  (#05–233;  1:500  dilution;  Upstate
Biotechnology, Lake Placid, NY) for 2 h, and then stained
with  secondary  antibody  (goat  anti-mouse  IgG-HRP
conjugate; 1:1,000 dilution; 1 h; Bio-Rad). After extensive
washing,  immunostaining  detected  by  the  antibody  was
visualized  by  enhanced  chemiluminescence  (Santa  Cruz
Biotechnology,  Santa  Cruz,  CA).  The  immunostain-
dependent chemiluminescence was recorded on film, and the
density of the immunostained dots was quantitated. Results
were  expressed  as  a  percent  of  values  detected  in  the
nondiabetic controls.
Expression of retinal intercellular adhesion molecule-1 and
cyclooxygenase-2:  Retinas  were  isolated,  sonicated,  and
centrifuged, and the supernatant was used for western blots.
Samples (50 µg) were fractionated by sodium dodecyl sulfate
PAGE (SDS–PAGE) and electroblotted onto nitrocellulose
membranes. The membranes were blocked in Tris-buffered
saline containing 0.02% Tween-20 (Sigma-Aldrich, St. Louis,
MO),  and  5%  nonfat  milk.  Antibodies  for  ICAM-1  and
cyclooxygenase  (COX)-2  (1:200  dilution;  Santa  Cruz
Biotechnology)  were  applied,  followed  by  secondary
antibody, for 1 h. After washing, the results were visualized
with enhanced chemiluminescence.
Tactile  allodynia:  A  standardized  testing  regime  was
performed to measure tactile allodynia, as reported previously
[24-26]. Animals were studied after 8 months of diabetes. A
series  of  Von  Frey  filaments  (Stoelting,  Wood  Dale,  IL),
starting with one that possessed a buckling weight of 2.0 g,
were applied in sequence to the plantar surface of the right
hindpaw with a pressure that caused the filament to buckle.
The lifting of the paw was recorded as a positive response,
and  the  next  lightest  filament  was  chosen  for  the  next
measurement. The absence of a response after 5 s prompted
use of the next filament of greater weight. This process was
continued until four measurements had been made after an
initial change in behavior, or until five consecutive negative
scores (a score of 15 g) or four positive scores (a score of 0.25
g)  had  resulted.  The  resulting  sequence  of  positive  and
negative scores was used to interpolate the 50% response
threshold, as described previously. All measurements were
performed  by  an  investigator  who  was  unaware  of  the
treatment group of individual animals.
Statistical analysis: Data were expressed as mean±standard
deviation (SD). Statistical analysis was performed using an
ANOVA (ANOVA), followed by Fischer’s test. A value of
p<0.05 was considered statistically significant.
RESULTS
Glycemia was elevated to a similar level in all diabetic groups.
The  average  glycated  hemoglobin  levels  over  the  entire
duration  of  the  10-month  experiment  were  3.2±0.2%,
12.5±0.4%,  12.1±0.8%,  12.6±0.9%,  and  12.6±0.8  for  the
nondiabetic, diabetic control, and diabetic groups (treated,
respectively, with 10, 100, and 300 µg mRAGE-Fc). Final
bodyweights in these same groups were 44±6.7 g, 27±2 g,
27±3 g, 26±3 g, and 27±2 g, respectively. Data from the two-
month  experiment  were  similar  (but  not  shown).
Administration  of  the  mRAGE-Fc  had  no  effect  on  the
glycemia  or  health  of  the  animals  at  any  of  the  doses
administered.
Inhibition of diabetes-induced retinal histopathology by
inhibitor of receptor for advanced glycation endproducts:
Long-term diabetes resulted in a significant increase in the
number of degenerate, acellular capillaries in the retinas of the
Figure 1. Administration of the RAGE-
immunoglobulin fusion protein for 10
months inhibited the diabetes-induced
increase  in  degenerate,  acellular
capillaries.  The  inhibitor  was
administered at three doses, 10, 100, 300
µg/day, for the entire duration of the
study.  Pericyte  loss  (as  indicated  by
ghosts where the pericytes used to be)
also tended to be increased by diabetes,
but  the  inhibitor  did  not  significantly
reduce  their  formation.  All  groups
contained at least ten animals.
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RAGE-Ig fusion protein significantly inhibited the diabetes-
induced degeneration of retinal capillaries. Diabetes tended to
increase  pericyte  degeneration  (pericyte  ghosts),  but  the
results  from  these  animals  did  not  achieve  statistical
significance.  Neither  did  diabetes  induce  a  significant
decrease in the number of cells in the retinal ganglion cell
layer (i.e., neurodegeneration); therefore, we could not assess
any  effects  of  the  RAGE  inhibitor  on  either  of  these
parameters (not shown).
In an effort to investigate the mechanism by which the
therapy mediated this beneficial effect on the degeneration of
retinal  capillaries  in  diabetes  cases,  we  measured  several
parameters related especially to inflammation and nitrative
(oxidative)  stress.  These  were  physiologic  and  molecular
abnormalities that have been found in other studies to be
associated  with  (and  possibly  causally  related  to)  the
development of the early stages of diabetic retinopathy.
Intercellular adhesion molecule-1 and leukostasis: Since
ICAM-1 expression on endothelial cells plays a critical role
in inflammation through the adhesion of white blood cells to
the  vessel  wall  (leukostasis),  we  measured  the  effect  of
diabetes and the therapy on the expression of ICAM-1 in
retinas and on leukostasis. Figure 2 and Figure 3 show that
diabetes of two months’ duration resulted in a significant
increase  in  the  expression  of  retinal  ICAM-1  and  in  the
number of leukocytes adherent to the retinal blood vessels
(p<0.05).  Administration  of  the  RAGE-Ig  fusion  protein
resulted  in  a  dose-dependent  effect  on  the  expression  of
ICAM.  The  highest  dose  significantly  inhibited  this
expression, although the lowest dose actually increased the
expression of the adhesion molecule above that observed in
the diabetic controls. Leukostasis tended to be inhibited in
these animals treated with the RAGE-Ig fusion protein, but
the inhibition did not achieve statistical significance.
Accumulation of albumin in neural retinas: Diabetes after
2 months resulted in a significant increase in the levels of
immunoreactive  albumin  in  the  nonvascular  retina  (i.e.,
between vessels) in each of the four retinal layers studied
(Figure 4A-D). Accumulation of the blood protein, albumin,
in the neural retina has been viewed as a marker of increased
vascular permeability. In the outer nuclear layer (Figure 4A),
outer plexiform layer (Figure 4B), and inner nuclear layer
(Figure 4C), all three doses of the RAGE-Ig fusion protein
significantly inhibited the accumulation of albumin in the
neural retina. In the inner plexiform layer (Figure 4D), the
100 µg and 300 µg doses of the RAGE-Ig fusion protein
significantly (but only partially) inhibited albumin leakage,
while the 10 µg dose had no effect.
Nitration  of  retinal  proteins  and  cyclooxygenase-2
expression:  The  nitration  of  proteins  is  regarded  as  a
parameter  of  both  oxidative  and  nitrative  stress.  Figure  5
shows that retinas from diabetic mice exhibited a significant
increase in the nitration of retinal proteins, compared to the
nitration  levels  detected  in  retinas  from  the  nondiabetic
animals (p<0.05). The RAGE inhibitor significantly inhibited,
in  a  dose-dependent  manner,  this  post-translational
modification. Expression of the protein band corresponding
to COX-2 did not increase in diabetic animals and did not
change in animals getting the therapy (not shown).
Tactile allodynia: The beneficial effects of this RAGE
inhibitor in diabetes were not limited to the retina. Figure 6
Figure 2. Only the highest dose of the
receptor  for  advanced  glycation
endproducts  (RAGE)  inhibitor
significantly  inhibited  the  diabetes-
induced increase in retinal intercellular
adhesion  molecule-1  (ICAM-1)
expression. Diabetics were treated with
0, 10, 100, or 300 μg/day of the RAGE-
Immunoglobulin  fusion  protein.  Only
the  highest  dose  of  inhibitor
significantly inhibited retinal ICAM-1
expression below that seen in control
diabetics. The duration of diabetes and
drug administration was 2 months. n=6–
10 in all groups.
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nerves to tactile allodynia in the diabetic control mice, and
administration of the two highest doses of the RAGE inhibitor
significantly inhibited the diabetes-induced hypersensitivity
of this sensory function. The lowest dose of drug (10 µg) had
a partial yet still significant effect.
DISCUSSION
RAGE  has  been  postulated  to  contribute  to  diabetic
complications by binding a variety of molecules, including
AGEs,  HMGB1,  S100,  and  integrins  [6,8,27-29].  Such
interactions lead to inflammatory processes, including the
upregulation of adhesion molecules, generation of cytokines
and reactive oxygen species, and upregulation of monocyte
chemoattractant  protein  1,  at  least  in  part  through  the
activation of NF-ĸB [7,8,30-37]. The mechanisms by which
RAGE inhibitors have been postulated to work include by
being  a  scavenger  for  soluble  AGEs,  by  acting  as  a
competitive antagonist for membrane-bound RAGEs and for
the full-length biologically active RAGEs, and by binding
HMGB1 to prevent its interaction with membrane RAGEs
[16].
The RAGE inhibitor fusion protein was able to inhibit
important histopathology in the retinas of diabetic mice—a
finding  consistent  with  a  prior  study  in  which  early
retinopathy  was  inhibited  using  sRAGEs  as  competitive
inhibitors  of  RAGE  binding  [9].  We  have  extended  the
findings of that study by also demonstrating the successful use
of  a  fusion  protein  to  inhibit  the  histopathology,  and  by
demonstrating that the drug’s effects on histopathology seem
not to be explained by its effects on several molecular changes
previously postulated to be important in the pathogenesis of
retinopathy.
An important feature of our study was that we tested the
therapy with three dosage levels. All three doses of the therapy
tested  significantly  inhibited  the  diabetes-induced
degeneration of the retinal vasculature. Likewise, all three
doses of the drug also seemed to inhibit any diabetes-induced
increase  in  albumin  accumulation  in  the  neural  retina.
Surprisingly, some abnormalities that have previously been
postulated to contribute to the development of retinal vascular
injury and retinopathy were not similarly inhibited by all doses
of our RAGE inhibitor.
Prior studies have demonstrated that RAGE serves as an
adhesion receptor that interacts with integrins and facilitates
the recruitment of proinflammatory leukocytes at the sites of
inflammation, further enhancing the inflammatory state [27,
38-40]. Moreover, diabetes induces RAGE on retinal Müller
cells [9,41], endothelial cells [42], and leukocytes [43]. Given
these observations, an unexpected finding in our studies was
that doses of mRAGE-Fc that had little or no apparent effect
on  several  parameters  of  inflammation  (e.g.,  leukostasis,
ICAM  expression),  nevertheless  significantly  inhibited
diabetes-induced  capillary  degeneration.  The  lack  of  any
effect of the present RAGE inhibitor on leukostasis seems
inconsistent with the earlier report that the sRAGE did inhibit
the increase in leukostasis, in vitro, in diabetes cases [38,42].
Nevertheless,  evidence  that  we  generated  previously  [20]
suggests that leukostasis, per se, is unlikely to be causal in the
development of early diabetic retinopathy in rodents.
Figure  3.  RAGE  inhibition  does  not
inhibit  leukostasis  in  the  retinal
vasculature.  Diabetes  (after  months’
duration)  significantly  increased  the
adherence of leukocytes to the retinal
vasculature,  and  the  RAGE-Ig  fusion
protein tended to inhibit this increase,
but  the  extent  of  inhibition  was  not
statistically  significant  at  any  dose.
n=6–10 in all groups.
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leukostasis did not always parallel its effects on capillary
degeneration, the effects of the drug on nitrative stress and
leakage of albumin were closely associated with capillary
degeneration. All three doses of the RAGE inhibitor blocked
protein nitration, leakage of albumin into the neural retina, and
capillary degeneration. Increased vascular permeability in the
retinas from diabetic animals has been linked to the presence
of  nitric  oxide  [13],  so  it  might  be  that  the  inhibition  of
albumin leakage detected by us using the RAGE inhibitor was
secondary to the effects from nitric oxide generation. Previous
studies by us and others have demonstrated that the diabetes-
induced  degeneration  of  retinal  capillaries  in  animals  is
essentially  prevented  in  diabetic  mice  deficient  in  the
inducible isoform of nitric oxide synthase, or is prevented if
wild-type diabetics are given aminoguanidine, an inhibitor of
the nitric oxide synthase [17,18,44-46].
AGE–RAGE  interactions  have  been  shown  to  induce
oxidative  stress,  to  upregulate  NF-ĸB  and  related
proinflammatory  genes  in  peripheral  nerves,  and  to
exaggerate  neurologic  dysfunction  [47-49].  Moreover,
diabetic mice (like human patients) develop altered nerve
function  [50],  and  diabetic  mice  lacking  RAGE  have
attenuated features of neuropathy and limited activation of
potentially detrimental signaling pathways [51]. Therefore,
we  investigated  the  effect  of  the  RAGE  inhibitor  on  the
dysfunction of peripheral nerves in diabetes cases. Since an
appreciable  number  of  diabetic  patients  develop
Figure 4. RAGE-Ig fusion protein inhibited albumin accumulation in the neural retina. Diabetes resulted in a significant increase in the levels
of immunoreactive albumin in the nonvascular retina (i.e., between vessels) in the A: outer nuclear layer, B: outer plexiform layer, C: inner
nuclear layer, and D: inner plexiform layer. All three treatment doses doses normalized albumin leakage in all layers except in the inner
plexiform layer, where only the two highest doses of the RAGE-Ig fusion protein significantly inhibited the leakage of albumin. n=6–10 in
all groups.
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with the reduced peripheral sensitivity that also develops in
diabetes), we assessed effects of the drug on sensitivity to
tactile allodynia in peripheral nerves. In our study, all three
doses of the RAGE inhibitor blocked the diabetes-induced
tactile allodynia, indicating that RAGE plays a role in at least
some aspects of sensory nerve dysfunction in diabetes cases.
Similar  beneficial  effects  on  tactile  allodynia  have  been
reported  following  inhibition  of  tumor  necrosis  factor  in
diabetic mice [52].
In conclusion, our data indicates that the novel fusion
protein  inhibitor  of  RAGE  inhibited  the  diabetes-induced
degeneration and permeability of the retinal vasculature and
the dysfunction of peripheral sensory nerves. Interestingly,
Figure  5.  RAGE-Ig  fusion  protein
inhibited  nitration  of  retinal  proteins
(assessed as nitrotyrosine modification
of retinal proteins). All three doses of the
inhibitor  significantly  inhibited  the
nitration of retinal proteins compared to
that in diabetic controls. The duration of
diabetes was 2 months. n=6–10 in all
groups.
Figure  6.  RAGE-Ig  fusion  protein
inhibited  the  diabetes-induced
hypersensitivity  to  tactile  allodynia
(light touch). Diabetic controls moved
their legs at a lower pressure, indicating
that  they  had  increased  sensitivity  to
touch. The inhibitor was administered at
three doses of 10, 100, and 300 µg/day,
and the duration of diabetes and drug
administration was 2 months. n=6–10 in
all groups.
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permeability occurred at doses of the drug that did not correct
several biochemical or physiologic abnormalities that have
been postulated to contribute to the vascular disease. This
difference in dose sensitivity between the effects on capillary
leakage/degeneration and biochemical abnormalities should
help  focus  attention  on  those  abnormalities  that  are  most
strongly  correlated  with  (and  the  likely  cause  of)  the
development of diabetic histopathology. RAGE continues to
be a promising target for the pharmacologic treatment and
prevention of diabetic complications in the eye and nerve.
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